Bevacizumab

Generic Name
Bevacizumab
Brand Names
Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
Drug Type
Biotech
Chemical Formula
-
CAS Number
216974-75-3
Unique Ingredient Identifier
2S9ZZM9Q9V
Background

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.

In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. There are also biosimilars of bevacizumab available, such as bevacizumab-awwb, bevacizumab-maly, and bevacizumab-adcd.

Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI). As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.

Indication

As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer; and recurrent glioblastoma.

Interestingly, bevacizumab is currently under investigation for the treatment of COVID-19 complications including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Associated Conditions
Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Associated Therapies
First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

First Posted Date
2007-04-04
Last Posted Date
2022-05-03
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
110
Registration Number
NCT00456261
Locations
🇺🇸

Northeast Alabama Regional Medical Center, Anniston, Alabama, United States

🇺🇸

Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States

🇺🇸

NEA Baptist Clinic, Jonesboro, Arkansas, United States

and more 15 locations

High-dose Bevacizumab in Advanced Renal Carcinoma Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-04-04
Last Posted Date
2014-12-22
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
119
Registration Number
NCT00455975
Locations
🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

🇺🇸

Northeast Georgia Medical Center, Gainesville, Georgia, United States

and more 10 locations

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2007-03-15
Last Posted Date
2015-11-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
64
Registration Number
NCT00448019
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

First Posted Date
2007-03-12
Last Posted Date
2012-06-26
Lead Sponsor
Sanofi
Target Recruit Count
127
Registration Number
NCT00446030
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2007-03-09
Last Posted Date
2012-06-28
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
43
Registration Number
NCT00445406
Locations
🇨🇭

Universitaetsspital-Basel, Basel, Switzerland

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-03-08
Last Posted Date
2021-10-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
52
Registration Number
NCT00444535
Locations
🇺🇸

Novartis Investigative Site, Sleepy Hollow, New York, United States

Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2007-03-07
Last Posted Date
2013-01-30
Lead Sponsor
Austrian Society Of Surgical Oncology
Target Recruit Count
43
Registration Number
NCT00444041
Locations
🇦🇹

Medical University Hospital Vienna, Vienna, Austria

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2007-02-27
Last Posted Date
2016-03-17
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
6
Registration Number
NCT00440973
Locations
🇺🇸

Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

First Posted Date
2007-02-19
Last Posted Date
2020-11-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT00436215
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma

First Posted Date
2007-02-13
Last Posted Date
2017-07-18
Lead Sponsor
Genentech, Inc.
Target Recruit Count
214
Registration Number
NCT00434252
© Copyright 2024. All Rights Reserved by MedPath